ArticleJournal of translational medicine2014
Azithromycin is able to control Toxoplasma gondii infection in human villous explants.
Article in Journal of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Azithromycin versus azithromycin-pyrimethamine and sulfadiazine-pyrimethamine for the treatment of ocular toxoplasmosis: a retrospective comparative case-series.Eye (London, England) · 2026Article
- Quercetin ReducesInternational journal of molecular sciences · 2026Article
- Review
- Prenylated chalcone analog-mediated Inhibition of Toxoplasma gondii growth in human trophoblast cell line and villous explants.Scientific reports · 2025Article
- Insights into the Role of Proteolytic and Adhesive Domains of Snake Venom Metalloproteinases fromToxins · 2025Article
- Article
- Leaf hydroalcoholic extract and oleoresin fromFrontiers in cellular and infection microbiology · 2023Article
- Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum.International journal for parasitology. Drugs and drug resistance · 2022Article
- The ethanolic extract of the fungusCurrent research in microbial sciences · 2022Article
- Cyclooxygenase (COX)-2 modulates Toxoplasma gondii infection, immune response and lipid droplets formation in human trophoblast cells and villous explants.Scientific reports · 2021Article
- Copaifera spp. oleoresins impair Toxoplasma gondii infection in both human trophoblastic cells and human placental explants.Scientific reports · 2020Article
- Modeling the Ruminant Placenta-Pathogen Interactions in Apicomplexan Parasites: Current and Future Perspectives.Frontiers in veterinary science · 2020Review
- Biogenic Silver Nanoparticles Can ControlFrontiers in microbiology · 2020Article
- Cellular immune response and scanning electron microscopy in the evaluation of Moringa leaves aqueous extract effect onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019Article
- Brazilian strains of Toxoplasma gondii are controlled by azithromycin and modulate cytokine production in human placental explants.Journal of biomedical science · 2019Article
- Cyclooxygenase (COX)-2 Inhibitors ReduceFrontiers in microbiology · 2019Article
- Enrofloxacin and Toltrazuril Are Able to ReduceFrontiers in cellular and infection microbiology · 2017Article
- A Systematic Review ofFrontiers in microbiology · 2017Review
- Malaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a review.Infectious diseases of poverty · 2015Review
- An eye for azithromycin: review of the literature.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough Toxoplasma gondii infection is normally asymptomatic, severe cases of toxoplasmosis may occur in immunosuppressed patients or congenitally infected newborns. When a fetal infection is established, the recommended treatment is a combination of pyrimethamine, sulfadiazine and folinic acid (PSA). The aim of the present study was to evaluate the efficacy of azithromycin to control T. gondii infection in human villous explants.
methodsCultures of third trimester human villous explants were infected with T. gondii and simultaneously treated with either PSA or azithromycin. Proliferation of T. gondii, as well as production of cytokines and hormones by chorionic villous explants, was analyzed.
resultsTreatment with either azithromycin or PSA was able to control T. gondii infection in villous explants. After azithromycin or PSA treatment, TNF-α, IL-17A or TGF-β1 levels secreted by infected villous explants did not present significant differences. However, PSA-treated villous explants had decreased levels of IL-10 and increased IL-12 levels, while treatment with azithromycin increased production of IL-6. Additionally, T. gondii-infected villous explants increased secretion of estradiol, progesterone and HCG+β, while treatments with azithromycin or PSA reduced secretion of these hormones concurrently with decrease of parasite load.
conclusionsIn conclusion, these results suggest that azithromycin may be defined as an effective alternative drug to control T. gondii infection at the fetal-maternal interface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.